Latest Conference Articles

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

Harmeet S. Bedi, MD, discusses the important role of pulmonologists in the diagnosis and management of patients with lung cancer.

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer. 

Selective estrogen receptor degraders are becoming increasingly important in the treatment of ER-positive metastatic breast cancer.

Chemoimmunotherapy combinations have transformed the treatment landscape for patients with triple-negative breast cancer, but balancing potential efficacy with the risk of toxicity with these regimens is critical in both the metastatic and early-stage settings.

By adapting adjuvant therapy based on responses to preoperative therapy, investigators may be able to change long term outcomes for patients with HER2-positive breast cancer, creating a paradigm shift in the space.

Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.

Treatment with darolutamide induced a low cumulative incidence of hormone treatment–related adverse effects that was comparable to treatment with placebo in patients with nonmetastatic castration-resistant prostate cancer, according to findings from a safety analysis of the phase 3 ARAMIS trial.

Intense androgen receptor inhibition with neoadjuvant apalutamide did not complicate robotic prostatectomy surgical outcomes.

Patients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood of experiencing respiratory complications and mortality than those without the virus.

Sequential combination treatment with mytomicin chemotherapy and Bacillus Calmette-Guérin (BCG) showed comparable safety compared with BCG alone in patients with high-risk non-muscle–invasive bladder cancer.

Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.

Vinayak G. Wagaskar, MBBS, discusses the rationale to evaluate the relationship between obesity paradigm and outcomes in prostate cancer.

The provision of urologic care underwent a significant decline during the height of the COVID-19 pandemic across all demographic groups and practice settings in the United States, regardless of the timing of stay-at-home order mandates.

The landscape of immunotherapy biomarkers is rapidly evolving, and future developments are likely to have an impact on patients and clinicians alike.

The field of targeted therapy for patients with non–small cell lung cancer has grown exponentially in recent years, with inhibitors for RET, MET exon 14 skipping, and KRAS G12C mutations transforming the paradigm.

Next-generation sequencing plays a critical role in the diagnosis of patients with myeloid malignancies, but it also plays a necessary role in the identification of passenger mutations and subclonal events that go beyond founding drivers.

Practice-validating trials in cervical cancer, endometrial cancer, and ovarian cancer were the focus of the 2021 ASCO Annual Meeting in gynecologic oncology, each carrying relevant implications on extended therapy, surveillance, and biomarker testing.

Tafasitamab-cxix plus lenalidomide and R-CHOP may have synergistic potential and could represent a potential future treatment option for patients with newly diagnosed diffuse large B-cell lymphoma.

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials.

Compared to currently available therapies, treatment with axicabtagene ciloleucel induced substantial objective response rate, progression-free survival, time to next treatment and overall survival improvements in patients with relapsed/refractory follicular lymphoma.

The combination of naratuximab emtansine and rituximab yielded deep responses, and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma.

The addition of daratumumab to lenalidomide and dexamethasone continued to reduced the risk of death by 32% compared with Rd alone in patients with newly diagnosed multiple myeloma who are transplant ineligible after almost 5 years of follow-up.

Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior progression-free survival compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia.

Rusfertide has been shown to be an effective option for patients with polycythemia vera in that it reverses iron deficiency, improves disease-related symptoms, and eliminates the need for therapeutic phlebotomy.